Apogee Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Apogee Therapeutics, Inc. (APGE) had Debt Securities, Available-for-sale, Amortized Cost of $330.92 million as of 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-05-13
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $330.92M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $276.81M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $294.14M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-03-31 | $330.92M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $276.81M 10-Q · filed 2024-05-13 |
| 2023-09-30 | $294.14M 10-Q · filed 2023-11-13 |